Jing Lan- Director; Wenzhong Liang- Executive Director- WuXi AppTec
Drug-plasma protein binding is a fundamental parameter in drug development that directly affects how a compound is distributed, metabolized, and excreted. Only a drug’s unbound fraction is pharmacologically active, so accurate measurements are essential for understanding efficacy and safety. This information also guides dosage design, predicts potential drug-drug interactions, and shapes clinical decision-making.
However, accurately determining protein binding can be highly challenging. The challenges encompass the complexity of the biological samples, the diversity of endogenous proteins in plasma, and the binding kinetics between drugs and proteins. Analytical methods must address analyte stability, nonspecific binding, and sample handling to ensure reliable results.
Given these challenges, regulatory agencies require bioanalytical methods to demonstrate robust precision and accuracy. As drug molecules and therapies improve, the need for precise, reproducible, and compliant assessment methods is as high as it has ever been.
Comparing Bioanalytical Techniques for Drug-Plasma Protein Binding
Several established techniques are used to assess drug-plasma protein binding, each with unique strengths and limitations in sensitivity, accuracy, and throughput. Each method must balance speed, sensitivity, and potential experimental artifacts. For example, exhaustive extraction can disrupt binding equilibrium, while membrane-based methods may introduce nonspecific binding or matrix effects. The most common bioanalytical techniques in sample pretreatment include:
- Equilibrium Dialysis (ED): Considered the traditional gold standard, ED reliably separates free from bound drugs using a semipermeable membrane. However, it is slow and can be affected by nonspecific binding and volume shifts.
- Rapid Equilibrium Dialysis (RED): An optimized version of ED, RED significantly reduces equilibration time and minimizes complications like protein leakage, making it suitable for higher-throughput settings.
- Ultrafiltration: This fast, widely used technique separates free drugs via centrifugal force, but results can vary depending on membrane properties, temperature, and speed. Modified protocols aim to improve reproducibility.
- Analytical Ultracentrifugation: This technique offers highly accurate binding measurements and detailed characterization. However, more attention should be given to physical phenomena related to ultracentrifugation, such as sedimentation, back diffusion, and binding to plasma lipoproteins in the supernatant fluid.
- Solid Phase Microextraction (SPME): This emerging method enables rapid, automated measurement of free drugs with small sample volumes, correlating well with ED and offering workflow efficiencies.
Using MS in Drug-Plasma Protein Binding Studies
The primary focus in drug development is accurately quantifying the extent of binding, specifically, the unbound versus bound drug fractions. Mass spectrometry technology encompasses high sensitivity, specificity, and precision, enabling the determination of free drug concentrations in complex biological samples. In drug-plasma protein binding studies, sample pretreatment is typically carried out using rapid equilibrium dialysis and then followed by quantitation using liquid chromatography–tandem mass spectrometry (LC-MS/ MS). This enables highly sensitive and specific quantification of total and unbound drugs in complex plasma samples. This is critical for drugs with low unbound fractions, where precise measurement (i.e., picogram-per-milliliter levels) is required.
High-resolution MS (HRMS) and matrix-assisted laser desorption ionization (MALDI-MS) also offer unique advantages. HRMS excels in structural elucidation and the analysis of complex mixtures, while MALDI-MS is valuable for mapping drug distribution in tissues and specialized protein-ligand studies. Native MS and hydrogen/ deuterium exchange (HDX-MS) can also provide detailed insights into protein-ligand interactions and binding stoichiometry. However, these are often reserved for mechanistic or structural biology research rather than routine plasma protein binding assays.
Improving Quantification of Unbound Versus Bound Drug Fractions
LC-MS/MS’s ability to precisely quantify unbound and bound drug fractions has transformed pharmacokinetic and pharmacodynamic studies. Because only the unbound fraction is pharmacologically active, drug safety and efficacy are tied closely to accurate measurement. ED and ultrafiltration are the most effective methods for physically separating free from bound drugs. Due to their high sensitivity and excellent specificity, LC-MS/MS is well-suited for detecting target analytes at low concentration in complex biological matrices.
Subtle changes in protein binding are critical for evaluating drug-drug interactions or special patient populations. Pairing LC-MS/MS with ED or ultrafiltration ensures these changes are reliably detected and measured. Other MS-based techniques offer valuable mechanistic insights, but LC-MS/MS is the method of choice when quantifying unbound and total drug concentrations in plasma. It is also the best way to ensure safe and effective therapeutics.
Technical Considerations in MS Based Protein Binding Studies
MS is very helpful in quantitating drug-plasma protein binding analysis, but its application has technical challenges that must be carefully managed to ensure reliability. Ion suppression is the first significant challenge in MS-based assays. Often, compounds in plasma, including salts, proteins, and lipids, interfere with analyte ionization, reducing sensitivity and accuracy. These matrix effects are especially pronounced with electrospray ionization and can compromise quantitative results.
Robust sample preparation is also essential to minimize matrix effects and maximize analyte recovery. Techniques including protein precipitation, liquid-liquid, and solid-phase extraction can help remove interfering substances, but optimizing these steps is critical. Inefficient extraction can lead to analyte loss, while poor cleanup may leave contaminants that distort results. Even slight variations in sample preparation can introduce significant variability, affecting accuracy and reproducibility. Optimizing and validating all preparation steps - according to each drug and matrix - is necessary to ensure consistent, high-quality data.
Finally, recent advances in tandem MS techniques coupled with HPLC or UHPLC have improved sensitivity, selectivity, and throughput.
Regulatory Considerations for Protein Binding Studies
Drug-plasma protein binding studies are subject to rigorous regulatory scrutiny because the data directly informs drug safety, efficacy, and dosing recommendations. As stipulated in ICH M12 regulation ‘Drug Interaction Studies’, bioanalytical methods for determining protein binding assay must demonstrate adequate precision and accuracy. The core experiments of sensitivity, specificity, accuracy, precision and repeatability of biological analysis methods will be carried out. Regulators expect each technique to be fully characterized and validated for its intended use. This ensures that measuring free and bound drug fractions is reliable and reproducible across different study phases and sample types.
For MS-based assays, the validation process includes:
- At least three independent runs to establish accuracy and precision.
- Calibration curves to define the quantitation range.
- Determination of the lower limit of quantitation (LLOQ) to ensure sensitivity.
- Experiments to assess selectivity and specificity confirm that the method distinguishes the analyte from endogenous substances and potential interferences.
- Investigation and measurement of the fraction unbound in plasma (Fu).
- Stability studies to ensure the analyte remains unchanged during sample collection, storage, and analysis.
- Assessment of recovery and matrix effects to confirm that the method is robust in the presence of complex biological matrices.
Regulators clearly expect comprehensive validation data. So, selecting and validating bioanalytical techniques for protein binding studies requires demonstrating that the method is fit for purpose, with all experiments, results, and supporting data reported and justified. ICH M12 has promoted consistency in the design, conduct, and interpretation of drug-drug interaction (DDI) and protein binding studies. This global alignment streamlines submissions and ensures that others will accept data generated in one region if it meets these harmonized standards.
The Future of MS in Drug-Protein Binding Studies
MS has established itself as an indispensable tool in drug development, and its role in drug-protein binding studies is poised to expand even further as technology advances. Scientists expect MS to become even more sensitive, faster, and more automated, driven by hardware improvements and integrating artificial intelligence (AI) and machine learning (ML) into existing platforms. Some of the most promising areas of development include:
- Integrative structural approaches: Combining MS with techniques such as NMR, X-ray crystallography, and Cryo-EM provides a complete understanding of protein complexes and drug binding at an atomic level.
- AI-driven analysis: AI and ML are revolutionizing MS data interpretation, enabling more accurate predictions of protein interactions and streamlining bioanalytical workflows.
The outlook for MS in drug-protein binding studies is bright. Emerging techniques and technology are set to revolutionize how researchers understand and quantify drug-protein interactions. These developments promise to enhance the accuracy and efficiency of bioanalytical assays and set new standards in drug discovery, development, and personalized medicine.
A Final Word on MS-based Drug Plasma Protein Binding
As drug development becomes more complex, precisely measuring drug-plasma protein binding is fundamental to ensuring safety, efficacy, and regulatory compliance. MS has become the preferred method for these analyses, and ongoing advancements in instrumentation, automation, and data analytics further elevate its capabilities. As technology converges with other structural biology tools, it promises to unlock even deeper insights into drug-protein interactions, accelerating the path from discovery to patient care.
Author Details
Ms. Jing Lan joined WuXi AppTec in 2007 and supports numerous bioanalysis projects in LC-MS/MS for MNCs, biotech and domestic pharmaceutical companies. Ms. Lan has been with WuXi AppTec for more than 17 years and has nearly 20 years of GLP-regulated bioanalytical experience in LC-MS/ MS. She is in charge of the bioanalysis of domestic generic drugs and innovative drugs, and she leads the team to support nearly 200+ BE projects, holds 100+ CFDI and NMPA inspections and has received 80+ drug approvals. Ms. Lan is also a lecturer at the NMPA Advanced Research Institute, participating in the Phase I Clinical Trial Biological Sample Analysis training course. Ms. Lan also participated in the translation of the book “Handbook of LC-MS Bioanalysis. Best Practices, Experimental Protocols, and Regulations”. Ms. Lan holds her Master’s degree in Research Center of Drug Metabolism from Jilin University.
Dr. Wenzhong Liang joined WuXi AppTec in 2012 and serves our international clients, providing technical support for the Global BAS teams in the U.S. and China. Dr. Liang has over 20 years of experience in regulated bioanalysis and GLP laboratory management. He has hosted more than 200 inspections from global regulatory agencies, including China’s NMPA, the FDA in the U.S., the OECD, and others, and commands a deep understanding of regulations in this field. Dr. Liang is a subject matter expert in small molecule bioanalysis and has been a member of the first Professional Committee of Pharmaceutical Bioanalysis of the Chinese Pharmaceutical Association since 2020.
Publication Details
This article appeared in American Pharmaceutical Review:Vol. 28, No. 4
May/June 2025Pages: 40-42
Subscribe to our e-Newsletters.
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!